ATE383168T1 - Fgf-2 zur behandlung von erkrankungen der peripheralen arterien - Google Patents

Fgf-2 zur behandlung von erkrankungen der peripheralen arterien

Info

Publication number
ATE383168T1
ATE383168T1 AT01946663T AT01946663T ATE383168T1 AT E383168 T1 ATE383168 T1 AT E383168T1 AT 01946663 T AT01946663 T AT 01946663T AT 01946663 T AT01946663 T AT 01946663T AT E383168 T1 ATE383168 T1 AT E383168T1
Authority
AT
Austria
Prior art keywords
fgf
peripheral artery
artery disease
compositions
patient
Prior art date
Application number
AT01946663T
Other languages
English (en)
Inventor
Martha Whitehouse
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE383168T1 publication Critical patent/ATE383168T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT01946663T 2000-06-22 2001-06-22 Fgf-2 zur behandlung von erkrankungen der peripheralen arterien ATE383168T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21350400P 2000-06-22 2000-06-22
US26457201P 2001-01-26 2001-01-26
US27654901P 2001-03-16 2001-03-16
US09/886,856 US20020115603A1 (en) 2000-06-22 2001-06-21 Methods and compositions for the treatment of peripheral artery disease

Publications (1)

Publication Number Publication Date
ATE383168T1 true ATE383168T1 (de) 2008-01-15

Family

ID=27498936

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01946663T ATE383168T1 (de) 2000-06-22 2001-06-22 Fgf-2 zur behandlung von erkrankungen der peripheralen arterien

Country Status (8)

Country Link
US (3) US20020115603A1 (de)
EP (1) EP1324766B1 (de)
JP (1) JP2004501164A (de)
AT (1) ATE383168T1 (de)
AU (1) AU2001268680A1 (de)
CA (1) CA2414020A1 (de)
DE (1) DE60132343T2 (de)
WO (1) WO2001098346A2 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US20020115603A1 (en) * 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
US20030004753A1 (en) * 2001-06-27 2003-01-02 Blackshear William M. Management method of persons at risk of complications of arterial occlusive disease
WO2003087318A2 (en) * 2002-04-08 2003-10-23 Eugene Levin Truncated 24 kda basic fibroblast growth factor
JP4532092B2 (ja) * 2003-09-30 2010-08-25 泰彦 田畑 血管新生剤
US7346382B2 (en) 2004-07-07 2008-03-18 The Cleveland Clinic Foundation Brain stimulation models, systems, devices, and methods
RU2435578C2 (ru) * 2005-06-29 2011-12-10 Марс, Инкорпорейтед Возбуждение вазодилатации периферических кровеносных сосудов
US20090062309A1 (en) * 2007-08-28 2009-03-05 Antonio Delgado-Almeida Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor
US8812123B2 (en) * 2007-10-17 2014-08-19 Intelect Medical, Inc. Patient programmer with input and sensing capabilities
US9220889B2 (en) 2008-02-11 2015-12-29 Intelect Medical, Inc. Directional electrode devices with locating features
US8019440B2 (en) 2008-02-12 2011-09-13 Intelect Medical, Inc. Directional lead assembly
US9272153B2 (en) 2008-05-15 2016-03-01 Boston Scientific Neuromodulation Corporation VOA generation system and method using a fiber specific analysis
HUE035700T2 (en) 2008-11-07 2018-05-28 Galaxy Biotech Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2
US8461111B2 (en) * 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
CA2772330A1 (en) 2009-08-27 2011-03-03 The Cleveland Clinic Foundation System and method to estimate region of tissue activation
WO2011068997A1 (en) 2009-12-02 2011-06-09 The Cleveland Clinic Foundation Reversing cognitive-motor impairments in patients having a neuro-degenerative disease using a computational modeling approach to deep brain stimulation programming
WO2011130729A2 (en) 2010-04-16 2011-10-20 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
AU2011267853B2 (en) 2010-06-14 2016-12-08 Boston Scientific Neuromodulation Corporation Programming interface for spinal cord neuromodulation
JP2014513622A (ja) 2011-03-29 2014-06-05 ボストン サイエンティフィック ニューロモデュレイション コーポレイション 治療刺激提供システムのための通信インタフェース
US9592389B2 (en) 2011-05-27 2017-03-14 Boston Scientific Neuromodulation Corporation Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information
CA2844081A1 (en) 2011-08-09 2013-02-14 Boston Scientific Neuromodulation Corporation Remote control for blind clinical trials of electrical stimulation
WO2014025624A1 (en) 2012-08-04 2014-02-13 Boston Scientific Neuromodulation Corporation Techniques and methods for storing and transferring registration, atlas, and lead information between medical devices
JP6224106B2 (ja) 2012-08-28 2017-11-01 ボストン サイエンティフィック ニューロモデュレイション コーポレイション リード及び／又は刺激中心に関する臨床効果データの取込み及び可視化
WO2014070290A2 (en) 2012-11-01 2014-05-08 Boston Scientific Neuromodulation Corporation Systems and methods for voa model generation and use
US9332994B2 (en) 2013-07-12 2016-05-10 Vasoinnovations, Inc. Apparatus and method to stop bleeding
US20230018664A1 (en) * 2013-07-12 2023-01-19 Vasoinnovations, Inc. Method to stop bleeding after a catheterization procedure using a large bore sheath
US10213214B2 (en) 2013-07-12 2019-02-26 Vasoinnovations, Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US9668744B2 (en) 2015-08-05 2017-06-06 Vasoinnovations, Inc. Apparatus and method to stop bleeding
US9308000B2 (en) 2013-07-12 2016-04-12 Vasoinnovations, Inc. Method of transradial catheterization, device for ulnar artery compression, and method of use
US11564697B2 (en) 2013-07-12 2023-01-31 Vasoinnovations Inc. Apparatus and method to stop bleeding
US10888334B2 (en) 2013-07-12 2021-01-12 Vasoinnovations Inc. Apparatus and method to stop bleeding
US9949738B2 (en) 2013-07-12 2018-04-24 Vasoinnovations, Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US10342551B2 (en) * 2013-07-12 2019-07-09 Vasoinnovations Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
US9959388B2 (en) 2014-07-24 2018-05-01 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for providing electrical stimulation therapy feedback
US10272247B2 (en) 2014-07-30 2019-04-30 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming
US10265528B2 (en) 2014-07-30 2019-04-23 Boston Scientific Neuromodulation Corporation Systems and methods for electrical stimulation-related patient population volume analysis and use
EP3204112A1 (de) 2014-10-07 2017-08-16 Boston Scientific Neuromodulation Corporation Systeme, vorrichtungen und verfahren zur elektrischen stimulation mittels rückkopplung zur einstellung von stimulationsparametern
EP3268082B1 (de) 2015-05-26 2019-04-17 Boston Scientific Neuromodulation Corporation Systeme und verfahren zur analyse von elektrischer stimulation und auswahl oder manipulation von aktivierungsvolumina
US10780283B2 (en) 2015-05-26 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
US20160375248A1 (en) 2015-06-29 2016-12-29 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects
ES2940303T3 (es) 2015-06-29 2023-05-05 Boston Scient Neuromodulation Corp Sistemas de selección de parámetros de estimulación por uso de dianas y direccionamiento
US10071249B2 (en) 2015-10-09 2018-09-11 Boston Scientific Neuromodulation Corporation System and methods for clinical effects mapping for directional stimulation leads
WO2017127493A1 (en) * 2016-01-22 2017-07-27 Salk Institute For Biological Studies Fgf2 truncations and mutants and uses thereof
US10716942B2 (en) 2016-04-25 2020-07-21 Boston Scientific Neuromodulation Corporation System and methods for directional steering of electrical stimulation
WO2017223505A2 (en) 2016-06-24 2017-12-28 Boston Scientific Neuromodulation Corporation Systems and methods for visual analytics of clinical effects
WO2018044881A1 (en) 2016-09-02 2018-03-08 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and directing stimulation of neural elements
US10780282B2 (en) 2016-09-20 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters
EP3493876B1 (de) 2016-10-14 2021-03-17 Boston Scientific Neuromodulation Corporation Systeme zur closed-loop-bestimmung von stimulationsparametereinstellungen für ein elektrisches simulationssystem
AU2017391436B2 (en) 2017-01-03 2020-06-18 Boston Scientific Neuromodulation Corporation Systems and methods for selecting MRI-compatible stimulation parameters
US10589104B2 (en) 2017-01-10 2020-03-17 Boston Scientific Neuromodulation Corporation Systems and methods for creating stimulation programs based on user-defined areas or volumes
US10625082B2 (en) 2017-03-15 2020-04-21 Boston Scientific Neuromodulation Corporation Visualization of deep brain stimulation efficacy
US11357986B2 (en) 2017-04-03 2022-06-14 Boston Scientific Neuromodulation Corporation Systems and methods for estimating a volume of activation using a compressed database of threshold values
WO2018200040A1 (en) * 2017-04-26 2018-11-01 University Of Cincinnati Compositions of fibroblast growth factor ligands and methods of treating patients unergoing ischemia-reperfusion therapy
EP3651849B1 (de) 2017-07-14 2023-05-31 Boston Scientific Neuromodulation Corporation Schätzung der klinischen wirkungen von elektrischer stimulation
US10960214B2 (en) 2017-08-15 2021-03-30 Boston Scientific Neuromodulation Corporation Systems and methods for controlling electrical stimulation using multiple stimulation fields
JP7295141B2 (ja) 2018-04-27 2023-06-20 ボストン サイエンティフィック ニューロモデュレイション コーポレイション マルチモード電気刺激システム及び製造する及び使用する方法
EP3784332B1 (de) 2018-04-27 2023-04-26 Boston Scientific Neuromodulation Corporation Systeme zur visualisierung und programmierung der elektrischen stimulation
US12403315B2 (en) 2021-04-27 2025-09-02 Boston Scientific Neuromodulation Corporation Systems and methods for automated programming of electrical stimulation
WO2022265977A1 (en) 2021-06-15 2022-12-22 Boston Scientific Neuromodulation Corporation Methods and systems for estimating neural activation by stimulation using a stimulation system
US12527956B2 (en) 2021-12-09 2026-01-20 Boston Scientific Neuromodulation Corporation Methods and systems for monitoring or assessing movement disorders or other physiological parameters using a stimulation system
US12471831B2 (en) 2021-12-10 2025-11-18 Boston Scientific Neuromodulation Corporation Systems and methods for generating and using response maps for electrical stimulation
WO2023167872A1 (en) 2022-03-02 2023-09-07 Boston Scientific Neuromodulation Corporation Systems and methods for monitoring stimulation drift in an electrical stimulation system

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604293A (en) * 1985-09-12 1997-02-18 Scios Inc. Recombinant human basic fibroblast growth factor
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
CA2202511A1 (en) * 1994-10-12 1996-04-25 Laurence A. Roth Targeted delivery via biodegradable polymers
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1997023256A1 (en) * 1995-12-22 1997-07-03 Localmed, Inc. Localized intravascular delivery of growth factors for promotion of angiogenesis
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
EP2123292B1 (de) * 1998-09-03 2016-05-04 Novartis Vaccines and Diagnostics, Inc. FGF-2 angiogenische wirksame Einheitdosis und Verfahren zu ihrer Verwendung
US20030166550A1 (en) * 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
JP2002527401A (ja) * 1998-10-13 2002-08-27 カイロン コーポレイション Ｆｇｆの脈管形成的に有効な単位用量および投与方法
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US20020115603A1 (en) * 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease

Also Published As

Publication number Publication date
US20070135348A1 (en) 2007-06-14
DE60132343T2 (de) 2008-12-24
US20020115603A1 (en) 2002-08-22
JP2004501164A (ja) 2004-01-15
WO2001098346A3 (en) 2003-05-01
US7186407B2 (en) 2007-03-06
EP1324766A2 (de) 2003-07-09
EP1324766B1 (de) 2008-01-09
US20040209817A1 (en) 2004-10-21
US7541337B2 (en) 2009-06-02
AU2001268680A1 (en) 2002-01-02
CA2414020A1 (en) 2001-12-27
WO2001098346A2 (en) 2001-12-27
DE60132343D1 (de) 2008-02-21

Similar Documents

Publication Publication Date Title
ATE383168T1 (de) Fgf-2 zur behandlung von erkrankungen der peripheralen arterien
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
PT710114E (pt) Formulacao do factor viii de coagulacao
DE60327771D1 (de) Glp-1 und behandlungsmethode für diabetes
BR9507227A (pt) Formulaçao farmacêutica para administraçao subcutânea intramuscular ou intradérmica uso da mesma e de um derivado de extinçao de um fator recombinante VIII e processo para o tratamento de hemofilia
DE69533112D1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
EP1064000A4 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
WO2001027079A3 (en) Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
WO2002022163A1 (en) Remedies for ischemic diseases
DE69739050D1 (de) Verwendung von Thrombopoietin als Medikament zur Therapie und Vorbeugung der Thrombocytopenie
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
WO2002058720A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
DE69921348D1 (de) Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
RU2130773C1 (ru) Способ лечения саркомы капоши
EP1894570A3 (de) Verfahren und Zusammensetzungen zur Behandlung von Erkrankungen der peripheren Arterie
KR101255200B1 (ko) 자가면역 손상에 따른 중추 신경계의 신경 재생용ｅｇｆ/ｇｈｒｐ-6의 조합
RU2140270C1 (ru) Способ лечения идиопатического типа саркомы капоши
RU2021130022A (ru) Применение эпидермального фактора роста при лечении диабетической язвы стопы
ATE280584T1 (de) Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties